
### [MONDO:0001018](http://purl.obolibrary.org/obo/MONDO_0001018)
**Label:** lymphoblastic leukemia

**Subclasses:** [MONDO:0007190](http://purl.obolibrary.org/obo/MONDO_0007190) (leukemia, chronic lymphocytic, susceptibility to, 2), [MONDO:0019469](http://purl.obolibrary.org/obo/MONDO_0019469) (T-cell large granular lymphocyte leukemia), [MONDO:0018689](http://purl.obolibrary.org/obo/MONDO_0018689) (plasma cell leukemia), [MONDO:0014241](http://purl.obolibrary.org/obo/MONDO_0014241) (leukemia, acute lymphoblastic, susceptibility to, 3), [MONDO:0004948](http://purl.obolibrary.org/obo/MONDO_0004948) (chronic lymphocytic leukemia), [MONDO:0020511](http://purl.obolibrary.org/obo/MONDO_0020511) (precursor b-cell acute lymphoblastic leukemia), [MONDO:0004967](http://purl.obolibrary.org/obo/MONDO_0004967) (acute lymphoblastic leukemia (disease)), [MONDO:0020512](http://purl.obolibrary.org/obo/MONDO_0020512) (precursor T-cell acute lymphoblastic leukemia), [MONDO:0009539](http://purl.obolibrary.org/obo/MONDO_0009539) (lymphoblastic leukemia, acute, with lymphomatous features), [MONDO:0007897](http://purl.obolibrary.org/obo/MONDO_0007897) (leukemia, chronic lymphocytic), [MONDO:0012936](http://purl.obolibrary.org/obo/MONDO_0012936) (leukemia, chronic lymphocytic, susceptibility to, 5), [MONDO:0007243](http://purl.obolibrary.org/obo/MONDO_0007243) (Burkitts lymphoma), [MONDO:0013108](http://purl.obolibrary.org/obo/MONDO_0013108) (all), [MONDO:0013109](http://purl.obolibrary.org/obo/MONDO_0013109) (ALL2), [MONDO:0012935](http://purl.obolibrary.org/obo/MONDO_0012935) (leukemia, chronic lymphocytic, susceptibility to, 4), [MONDO:0012318](http://purl.obolibrary.org/obo/MONDO_0012318) (leukemia, chronic lymphocytic, susceptibility to, 1), [MONDO:0012934](http://purl.obolibrary.org/obo/MONDO_0012934) (leukemia, chronic lymphocytic, susceptibility to, 3), 

**Corr. equiv. classes:** [Orphanet:454714](http://www.orpha.net/ORDO/Orphanet_454714), [Orphanet:99860](http://www.orpha.net/ORDO/Orphanet_99860), [Orphanet:99861](http://www.orpha.net/ORDO/Orphanet_99861), [Orphanet:86872](http://www.orpha.net/ORDO/Orphanet_86872), [OMIM:113970](http://purl.obolibrary.org/obo/OMIM_113970), [OMIM:613065](http://purl.obolibrary.org/obo/OMIM_613065), [OMIM:151400](http://purl.obolibrary.org/obo/OMIM_151400), [OMIM:247640](http://purl.obolibrary.org/obo/OMIM_247640), [OMIM:613067](http://purl.obolibrary.org/obo/OMIM_613067), [Orphanet:67038](http://www.orpha.net/ORDO/Orphanet_67038), [OMIM:615545](http://purl.obolibrary.org/obo/OMIM_615545), [OMIM:612558](http://purl.obolibrary.org/obo/OMIM_612558), [OMIM:612557](http://purl.obolibrary.org/obo/OMIM_612557), [OMIM:609630](http://purl.obolibrary.org/obo/OMIM_609630), [OMIM:612559](http://purl.obolibrary.org/obo/OMIM_612559), [OMIM:109543](http://purl.obolibrary.org/obo/OMIM_109543), [Orphanet:543](http://www.orpha.net/ORDO/Orphanet_543), [Orphanet:513](http://www.orpha.net/ORDO/Orphanet_513), 

**Class expressions from DL-Learner:**

- [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) and [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) 22.62%
- [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) and [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) 22.62%
- [HP:0004377](http://purl.obolibrary.org/obo/HP_0004377) (Hematological neoplasm) 22.54%
- [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 22.41%
- [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) and [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) 22.41%
- [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) 20.81%
- [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) 20.62%
- [HP:0001871](http://purl.obolibrary.org/obo/HP_0001871) (Abnormality of blood and blood-forming tissues) 19.87%
- [HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes) 18.69%
- [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 18.69%
- [HP:0001871](http://purl.obolibrary.org/obo/HP_0001871) (Abnormality of blood and blood-forming tissues) and [HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system) 18.69%
- [HP:0000118](http://purl.obolibrary.org/obo/HP_0000118) (Phenotypic abnormality) 17.92%
- Thing 17.91%
- [HP:0000001](http://purl.obolibrary.org/obo/HP_0000001) (All) 17.91%
- [HP:0002715](http://purl.obolibrary.org/obo/HP_0002715) (Abnormality of the immune system) 16.45%


